Biogen’s new Alzheimer’s drug could take ‘some time’ to reach Medicare market: Laura Chico
Wedbush Securities Senior Vice President of biotech equity research Laura Chico says questions remain about the benefits and risks of Biogen’s experimental Alzheimer’s drug.
FDA officials will decide on July 6 whether to grant full approval to the new Alzheimer's treatment Leqembi, Japanese drugmaker Eisai and its U.S. partner Biogen said on Monday.
The drug, known chemically as lecanemab, is administered intravenously twice a month and has been shown to reduce brain amyloid plaque, a marker of Alzheimer's.
The FDA granted the drug accelerated approval for patients with mild or early cases of dementia in January based off a Phase 2 study.